Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines

Papillomavirus Research

Volumn 1, Issue , 2015, Pages 90-100

  Hartwig, Susanne ^a   Baldauf, Jean Jacques ^b   Dominiak Felden, Géraldine ^a   Simondon, François ^c,d   Alemany, Laia ^e   de Sanjosé, Silvia ^e   Castellsagué, Xavier ^e  

^a SANOFI PASTEUR   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Burden of disease; Cancer; Genital warts; HPV; HPV vaccine; Precancerous lesions

Indexed keywords

WART VIRUS VACCINE;

ANOGENITAL CANCER; ANUS CARCINOMA; ARTICLE; CANCER INCIDENCE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; EUROPE; FEMALE; GENITAL TRACT CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRECANCER; PREVALENCE; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVA CANCER; VULVAR INTRAEPITHELIAL NEOPLASIA; WART VIRUS;

EID: 84946948473     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2015.06.003     Document Type: Article

References (31)

1. IARC: Monographs on the Evaluation on Carcinogenic Risks to Humans. Volume 100: A Review of Human Carcinogens. Part B: Biological Agents, Lyon: International Agency for Research on Cancer, 2012.
2. European Centers for Disease Prevention and Control: Introduction of HPV Vaccines in EU Countries-An Update. Stockholm: European Centers for Disease Prevention and Control, 2012.
3. Tabrizi S.N., Brotherton J.M., Kaldor J.M., Skinner S.R., Cummins E., Liu B., Bateson D., McNamee K., Garefalakis M., Garland S.M. Fall in human papillomavirus prevalence following a national vaccination program. J. Infect. Dis. 2012, 206:1645-1651.
4. Mariani Luciano, Vici Patrizia, Suligoi Barbara, Checcucci-Lisi Giovanni, Drury Rosybel Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther 2015, 32:10-30.
5. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092.
6. Gertig D.M., Brotherton J.M., Budd A.C., Drennan K., Chappell G., Saville A.M. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013, 11(227).
7. Crowe E., Pandeya N., Brotherton J.M., Dobson A.J., Kisely S., Lambert S.B., Whiteman D.C. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014, 348:g1458.
8. Ali H., Donovan B., Wand H., Read T.R., Regan D.G., Grulich A.E., Fairley C.K., Guy R.J. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
9. Ali H., Guy R.J., Wand H., Read T.R., Regan D.G., Grulich A.E., Fairley C.K., Donovan B. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect. Dis. 2013, 13:140.
10. de Sanjosé S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., Tous S., Felix A., Bravo L.E., Shin H.R., Vallejos C.S., de Ruiz P.A., Lima M.A., Guimera N., Clavero O., Alejo M., Llombart-Bosch A., Cheng-Yang C., Tatti S.A., Kasamatsu E., Iljazovic E., Odida M., Prado R., Seoud M., Grce M., Usubutun A., Jain A., Suarez G.A., Lombardi L.E., Banjo A., Menéndez C., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11:1048-1056.
11. No Authors Listed: HPV Vaccine Works Against Nine Viral Types. Cancer Discov 4 (2014) OF2.
12. IARC. Website of the International Agency for Research on Cancer [www.iarc.fr].
13. IARC: Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Data Sources and Methods [http://globocan.iarc.fr/Pages/DataSource:and_methods.aspx].
14. Forman D., Bray F., Brewster D.H., Gombe Mbalawa C., Kohler B., Piñeros M., Steliarova-Foucher E., Swaminathan R., Ferlay J.: Cancer Incidence in Five Continents, vol. X. [http://ci5.iarc.fr].
15. European Commission: Eurostat homepage. [http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home].
16. Nygard M., Hansen B.T., Dillner J., Munk C., Oddsson K., Tryggvadottir L., Hortlund M., Liaw K.L., Dasbach E.J., Kjær S.K. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One 2014, 9:e88323.
17. Joura E.A., Ault K.A., Bosch F.X., Brown D., Cuzick J., Ferris D., Garland S.M., Giuliano A.R., Hernandez-Avila M., Huh W., Iversen O.E., Kjaer S.K., Luna J., Miller D., Monsonego J., Munoz N., Myers E., Paavonen J., Pitisuttithum P., Steben M., Wheeler C.M., Perez G., Saah A., Luxembourg A., Sings H.L., Velicer C. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol. Biomarkers Prevent. 2014, 23:1997-2008.
18. de Sanjosé S., Alemany L., Ordi J., Tous S., Alejo M., Bigby S.M., Joura E.A., Maldonado P., Laco J., Bravo I.G., Vidal A., Guimerà N., Cross P., Wain G.V., Petry K.U., Mariani L., Bergeron C., Mandys V., Sica A.R., Félix A., Usubutun A., Seoud M., Hernández-Suárez G., Nowakowski A.M., Wilson G., Dalstein V., Hampl M., Kasamatsu E.S., Lombardi L.E., Tinoco L., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur. J. Cancer 2013, 49:3450-3461.
19. Alemany L., Saunier M., Alvarado-Cabrero I., Quiros B., Salmeron J., Shin H.R., Pirog E.C., Guimerà N., Hernandez-Suarez G., Felix A., Clavero O., Lloveras B., Kasamatsu E., Goodman M.T., Hernandez B.Y., Laco J., Tinoco L., Geraets D.T., Lynch C.F., Mandys V., Poljak M., Jach R., Verge J., Clavel C., Ndiaye C., Klaustermeier J., Cubilla A., Castellsagué X., Bravo I.G., Pawlita M., et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int. J. Cancer 2014, [Epub ahead of print], May 10.
20. Nielsen A., Munk C., Kjaer S.K. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark. Int. J. Cancer 2012, 130:1168-1173.
21. Hartwig S., Syrjanen S., Dominiak-Felden G., Brotons M., Castellsagué X. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012, 12:30.
22. Kraut A.A., Schink T., Schulze-Rath R., Mikolajczyk R.T., Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect. Dis. 2010, 10:360.
23. Desai S., Wetten S., Woodhall S.C., Peters L., Hughes G., Soldan K. Genital warts and cost of care in England. Sex. Transm. Infect. 2011, 87:464-468.
24. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
25. Alemany L., Saunier M., Tinoco L., Quiros B., Alvarado-Cabrero I., Alejo M., Joura E.A., Maldonado P., Klaustermeier J., Salmerón J., Bergeron C., Petry K.U., Guimerà N., Clavero O., Murillo R., Clavel C., Wain V., Geraets D.T., Jach R., Cross P., Carrilho C., Molina C., Shin H.R., Mandys V., Nowakowski A.M., Vidal A., Lombardi L., Kitchener H., Sica A.R., Magaña-León C., et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur. J. Cancer 2014, 50:2846-2854.
26. Serrano B., Alemany L., Tous S., Bruni L., Clifford G.M., Weiss T., Bosch F.X., de Sanjosé S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect. Agents Cancer 2012, 7:38.
27. Lacey C.J., Lowndes C.M., Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24(Suppl. 3). S3-35-S3/41.
28. Donne A.J., Hampson L., Homer J.J., Hampson I.N. The role of HPV type in recurrent respiratory papillomatosis. Int. J. Pediatr. Otorhinolaryngol. 2010, 74:7-14.
29. Syrjanen K.J. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur. J. Obstet. Gynecol. Reprod. Biol. 1996, 65:45-53.
30. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008, 9:425-434.
31. van deNieuwenhof H.P., Massuger L.F., van der Avoort I.A., Bekkers R.L., Casparie M., Abma W., van Kempen L.C., de Hullu J.A., et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur. J. Cancer 2009, 45:851-856.